GB201522186D0 - Treatment of fibrosis - Google Patents

Treatment of fibrosis

Info

Publication number
GB201522186D0
GB201522186D0 GBGB1522186.4A GB201522186A GB201522186D0 GB 201522186 D0 GB201522186 D0 GB 201522186D0 GB 201522186 A GB201522186 A GB 201522186A GB 201522186 D0 GB201522186 D0 GB 201522186D0
Authority
GB
United Kingdom
Prior art keywords
fibrosis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1522186.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Singapore Health Services Pte Ltd And Nat University Of Singapore
Original Assignee
Singapore Health Services Pte Ltd And Nat University Of Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55274842&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB201522186(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Singapore Health Services Pte Ltd And Nat University Of Singapore filed Critical Singapore Health Services Pte Ltd And Nat University Of Singapore
Priority to GBGB1522186.4A priority Critical patent/GB201522186D0/en
Publication of GB201522186D0 publication Critical patent/GB201522186D0/en
Priority to EP18185326.8A priority patent/EP3428188A1/en
Priority to SM20180601T priority patent/SMT201800601T1/it
Priority to LTEP16822941.7T priority patent/LT3298040T/lt
Priority to PCT/EP2016/081430 priority patent/WO2017103108A1/en
Priority to DK16822941.7T priority patent/DK3298040T3/en
Priority to NZ744307A priority patent/NZ744307A/en
Priority to SG11201804836RA priority patent/SG11201804836RA/en
Priority to RS20181140A priority patent/RS57894B1/sr
Priority to US15/381,622 priority patent/US10035852B2/en
Priority to JP2018531325A priority patent/JP6753933B2/ja
Priority to AU2016369407A priority patent/AU2016369407B2/en
Priority to CN201680074600.XA priority patent/CN108495861B/zh
Priority to EP18185323.5A priority patent/EP3431498A1/en
Priority to PT16822941T priority patent/PT3298040T/pt
Priority to CN202310056618.9A priority patent/CN116036284A/zh
Priority to SG10201908380T priority patent/SG10201908380TA/en
Priority to HRP20181692TT priority patent/HRP20181692T1/hr
Priority to PL16822941T priority patent/PL3298040T3/pl
Priority to CA3007750A priority patent/CA3007750A1/en
Priority to EP18176010.9A priority patent/EP3428186A1/en
Priority to EP16822941.7A priority patent/EP3298040B1/en
Priority to TR2018/15415T priority patent/TR201815415T4/tr
Priority to KR1020247034233A priority patent/KR20240152973A/ko
Priority to HK18113247.4A priority patent/HK1254287B/xx
Priority to SI201630104T priority patent/SI3298040T1/sl
Priority to EP18185321.9A priority patent/EP3428187A1/en
Priority to EP18188947.8A priority patent/EP3431499A1/en
Priority to ES16822941T priority patent/ES2692773T3/es
Priority to KR1020187020275A priority patent/KR102720360B1/ko
Priority to HUE16822941A priority patent/HUE041433T2/hu
Priority to EP18188951.0A priority patent/EP3431500A1/en
Priority to US15/988,463 priority patent/US10106603B2/en
Priority to ZA2018/03727A priority patent/ZA201803727B/en
Priority to US16/055,283 priority patent/US10894826B2/en
Priority to US16/055,295 priority patent/US10927169B2/en
Priority to US16/055,270 priority patent/US10894825B2/en
Priority to US16/055,261 priority patent/US10865239B2/en
Priority to US16/055,251 priority patent/US10870697B2/en
Priority to US16/055,304 priority patent/US10822405B2/en
Priority to US16/055,245 priority patent/US10870696B2/en
Priority to US16/055,319 priority patent/US10894827B2/en
Priority to US16/106,047 priority patent/US10889642B2/en
Priority to US16/106,041 priority patent/US10865240B2/en
Priority to US16/106,050 priority patent/US10899832B2/en
Priority to US16/106,044 priority patent/US10865241B2/en
Priority to AU2018229484A priority patent/AU2018229484B9/en
Priority to AU2018229483A priority patent/AU2018229483B2/en
Priority to AU2018229485A priority patent/AU2018229485B2/en
Priority to AU2018229486A priority patent/AU2018229486B2/en
Priority to AU2018229482A priority patent/AU2018229482B2/en
Priority to AU2018229487A priority patent/AU2018229487B2/en
Priority to CY181101130T priority patent/CY1120950T1/el
Priority to JP2020139045A priority patent/JP7102474B2/ja
Priority to US17/110,094 priority patent/US11939374B2/en
Priority to US18/436,088 priority patent/US20240360211A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1522186.4A 2015-12-16 2015-12-16 Treatment of fibrosis Ceased GB201522186D0 (en)

Priority Applications (56)

Application Number Priority Date Filing Date Title
GBGB1522186.4A GB201522186D0 (en) 2015-12-16 2015-12-16 Treatment of fibrosis
EP18185326.8A EP3428188A1 (en) 2015-12-16 2016-12-16 Treatment of fibrosis of the cardiovascular system with antibodies which prevent il-11:il-11ralpha interaction
SM20180601T SMT201800601T1 (it) 2015-12-16 2016-12-16 Trattamento della fibrosi
LTEP16822941.7T LT3298040T (lt) 2015-12-16 2016-12-16 Fibrozės gydymas
PCT/EP2016/081430 WO2017103108A1 (en) 2015-12-16 2016-12-16 Treatment of fibrosis
DK16822941.7T DK3298040T3 (en) 2015-12-16 2016-12-16 TREATMENT OF FIBROSE
NZ744307A NZ744307A (en) 2015-12-16 2016-12-16 Treatment of fibrosis
SG11201804836RA SG11201804836RA (en) 2015-12-16 2016-12-16 Treatment of fibrosis
RS20181140A RS57894B1 (sr) 2015-12-16 2016-12-16 Tretman fibroze
US15/381,622 US10035852B2 (en) 2015-12-16 2016-12-16 Treatment of fibrosis
JP2018531325A JP6753933B2 (ja) 2015-12-16 2016-12-16 線維化の治療
AU2016369407A AU2016369407B2 (en) 2015-12-16 2016-12-16 Treatment of fibrosis
CN201680074600.XA CN108495861B (zh) 2015-12-16 2016-12-16 纤维化治疗
EP18185323.5A EP3431498A1 (en) 2015-12-16 2016-12-16 Treatment of fibrosis of the gastrointestinal tract with antibodies which prevent il-11:il-11ralpha interaction
PT16822941T PT3298040T (pt) 2015-12-16 2016-12-16 Tratamento da fibrose
CN202310056618.9A CN116036284A (zh) 2015-12-16 2016-12-16 纤维化治疗
SG10201908380T SG10201908380TA (en) 2015-12-16 2016-12-16 Treatment of fibrosis
HRP20181692TT HRP20181692T1 (hr) 2015-12-16 2016-12-16 Liječenje fibroze
PL16822941T PL3298040T3 (pl) 2015-12-16 2016-12-16 Leczenie zwłóknienia
CA3007750A CA3007750A1 (en) 2015-12-16 2016-12-16 Treatment of fibrosis
EP18176010.9A EP3428186A1 (en) 2015-12-16 2016-12-16 Treatment of fibrosis of the liver with antibodies which prevent il-11:il-11ralpha interaction
EP16822941.7A EP3298040B1 (en) 2015-12-16 2016-12-16 Treatment of fibrosis
TR2018/15415T TR201815415T4 (tr) 2015-12-16 2016-12-16 Fibroz tedavisi.
KR1020247034233A KR20240152973A (ko) 2015-12-16 2016-12-16 섬유증의 치료
HK18113247.4A HK1254287B (en) 2015-12-16 2016-12-16 Treatment of fibrosis
SI201630104T SI3298040T1 (sl) 2015-12-16 2016-12-16 Zdravljenje fibroze
EP18185321.9A EP3428187A1 (en) 2015-12-16 2016-12-16 Treatment of fibrosis of the respiratory system with antibodies which prevent il-11:il-11ralpha interaction
EP18188947.8A EP3431499A1 (en) 2015-12-16 2016-12-16 Treatment of fibrosis of the eye with antibodies which prevent il-11:il-11ralpha interaction
ES16822941T ES2692773T3 (es) 2015-12-16 2016-12-16 Tratamientos para la fibrosis
KR1020187020275A KR102720360B1 (ko) 2015-12-16 2016-12-16 섬유증의 치료
HUE16822941A HUE041433T2 (hu) 2015-12-16 2016-12-16 Fibrózis kezelése
EP18188951.0A EP3431500A1 (en) 2015-12-16 2016-12-16 Treatment of fibrosis of the skin with antibodies which prevent il-11:il-11ralpha interaction
US15/988,463 US10106603B2 (en) 2015-12-16 2018-05-24 Treatment of fibrosis
ZA2018/03727A ZA201803727B (en) 2015-12-16 2018-06-05 Treatment of fibrosis
US16/055,283 US10894826B2 (en) 2015-12-16 2018-08-06 Treatment of fibrosis with interleukin-11 receptor alpha antibody
US16/055,295 US10927169B2 (en) 2015-12-16 2018-08-06 Treatment of fibrosis with Interleukin-11 receptor alpha antibody
US16/055,270 US10894825B2 (en) 2015-12-16 2018-08-06 Treatment of fibrosis with interleukin-11 antibody
US16/055,261 US10865239B2 (en) 2015-12-16 2018-08-06 Treatment of fibrosis with interleukin-11 antibody
US16/055,251 US10870697B2 (en) 2015-12-16 2018-08-06 Treatment of fibrosis with interleukin-11 antibody
US16/055,304 US10822405B2 (en) 2015-12-16 2018-08-06 Treatment of fibrosis with IL-11 receptor alpha antibody
US16/055,245 US10870696B2 (en) 2015-12-16 2018-08-06 Treatment of fibrosis with interleukin-11 antibody
US16/055,319 US10894827B2 (en) 2015-12-16 2018-08-06 Treatment of fibrosis with interleukin-11 receptor alpha antibody
US16/106,047 US10889642B2 (en) 2015-12-16 2018-08-21 Treatment of fibrosis with interleukin-11 receptor alpha antibody
US16/106,041 US10865240B2 (en) 2015-12-16 2018-08-21 Treatment of fibrosis with interleukin-11 antibody
US16/106,050 US10899832B2 (en) 2015-12-16 2018-08-21 Treatment of fibrosis with interleukin-11 receptor alpha antibody
US16/106,044 US10865241B2 (en) 2015-12-16 2018-08-21 Treatment of fibrosis with interleukin-11 antibody
AU2018229484A AU2018229484B9 (en) 2015-12-16 2018-09-13 Treatment of fibrosis
AU2018229483A AU2018229483B2 (en) 2015-12-16 2018-09-13 Treatment of fibrosis
AU2018229485A AU2018229485B2 (en) 2015-12-16 2018-09-13 Treatment of fibrosis
AU2018229486A AU2018229486B2 (en) 2015-12-16 2018-09-13 Treatment of fibrosis
AU2018229482A AU2018229482B2 (en) 2015-12-16 2018-09-13 Treatment of fibrosis
AU2018229487A AU2018229487B2 (en) 2015-12-16 2018-09-13 Treatment of fibrosis
CY181101130T CY1120950T1 (el) 2015-12-16 2018-10-31 Θεραπεια ινωσης
JP2020139045A JP7102474B2 (ja) 2015-12-16 2020-08-20 線維化の治療
US17/110,094 US11939374B2 (en) 2015-12-16 2020-12-02 Treatment of fibrosis
US18/436,088 US20240360211A1 (en) 2015-12-16 2024-02-08 Treatment of fibrosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1522186.4A GB201522186D0 (en) 2015-12-16 2015-12-16 Treatment of fibrosis

Publications (1)

Publication Number Publication Date
GB201522186D0 true GB201522186D0 (en) 2016-01-27

Family

ID=55274842

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1522186.4A Ceased GB201522186D0 (en) 2015-12-16 2015-12-16 Treatment of fibrosis

Country Status (24)

Country Link
US (16) US10035852B2 (enExample)
EP (7) EP3431499A1 (enExample)
JP (2) JP6753933B2 (enExample)
KR (2) KR20240152973A (enExample)
CN (2) CN116036284A (enExample)
AU (7) AU2016369407B2 (enExample)
CA (1) CA3007750A1 (enExample)
CY (1) CY1120950T1 (enExample)
DK (1) DK3298040T3 (enExample)
ES (1) ES2692773T3 (enExample)
GB (1) GB201522186D0 (enExample)
HR (1) HRP20181692T1 (enExample)
HU (1) HUE041433T2 (enExample)
LT (1) LT3298040T (enExample)
NZ (1) NZ744307A (enExample)
PL (1) PL3298040T3 (enExample)
PT (1) PT3298040T (enExample)
RS (1) RS57894B1 (enExample)
SG (2) SG10201908380TA (enExample)
SI (1) SI3298040T1 (enExample)
SM (1) SMT201800601T1 (enExample)
TR (1) TR201815415T4 (enExample)
WO (1) WO2017103108A1 (enExample)
ZA (1) ZA201803727B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
GB201621439D0 (en) * 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
US20180186871A1 (en) * 2016-12-16 2018-07-05 Singapore Health Services Pte Ltd. Il-11 antibodies
GB201716733D0 (en) * 2017-10-12 2017-11-29 Nat Univ Singapore Treatment of SMC mediated disease
GB201806918D0 (en) * 2018-04-27 2018-06-13 Enleofen Bio Pte Ltd Combination treatment for eye fibrosis
GB201809699D0 (en) * 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
GB201809700D0 (en) * 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
WO2020152122A1 (en) 2019-01-21 2020-07-30 Singapore Health Services Pte. Ltd. Treatment of hepatotoxicity
GB201902419D0 (en) * 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
KR20220050087A (ko) * 2019-05-03 2022-04-22 싱가포르 헬스 서비시즈 피티이 엘티디 대사성 질환의 치료 및 예방
GB201906291D0 (en) 2019-05-03 2019-06-19 Singapore Health Serv Pte Ltd Treatment and prevention of metabolic diseases
CN114390914A (zh) 2019-08-05 2022-04-22 诺沃库勒有限责任公司 通过抑制il11活性增加癌细胞对肿瘤治疗场(ttfield)的敏感性
KR102270700B1 (ko) * 2019-11-01 2021-06-30 한국과학기술연구원 폐 섬유증의 예방 또는 치료를 위한 올리고뉴클레오티드 중합체와 생체 적합성 양이온성 펩타이드로 이루어지는 폐 특이적 약물 전달체 및 이의 이용
GB202009292D0 (en) 2020-06-18 2020-08-05 Singapore Health Serv Pte Ltd Treatment and prevention of disease caused by type IV collagen dysfunction
JP2023537422A (ja) * 2020-08-13 2023-08-31 サンシャイン・レイク・ファーマ・カンパニー・リミテッド Ｉｌ－１１の抗体及びその使用
GB202017244D0 (en) 2020-10-30 2020-12-16 Nat Univ Singapore Methods to extend health-span and treat age-related diseases
CA3211686A1 (en) 2021-02-26 2022-09-01 Bayer Aktiengesellschaft Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding
WO2023006765A1 (en) 2021-07-26 2023-02-02 Boehringer Ingelheim International Gmbh Treatment and prevention of alcoholic liver disease
JP2024532620A (ja) 2021-08-30 2024-09-05 ラッセン・セラピューティクス１・インコーポレイテッド 抗ＩＬ－１１Ｒα抗体
CN115068442A (zh) * 2021-09-13 2022-09-20 荣灿生物医药技术(上海)有限公司 核酸的纳米颗粒组合物、其制备方法和用途
US20250082608A1 (en) 2021-12-16 2025-03-13 Singapore Health Services Pte Ltd. Treatment and prevention of glomerular disease
CN115414346B (zh) * 2022-08-29 2023-09-29 湖南复瑞生物医药技术有限责任公司 一种应用胺碘酮构造肺纤维化模型的方法
GB202218388D0 (en) 2022-12-07 2023-01-18 Vvb Bio Pte Ltd GP130 antigen-binding molecules
EP4702047A1 (en) 2023-04-25 2026-03-04 VVB Bio Pte. Ltd. Anti il-11 antibody
CN120518762B (zh) * 2023-06-05 2025-12-26 北京东方百泰生物科技股份有限公司 一种结合il-11的抗体、其抗原结合片段及应用
GB202311050D0 (en) 2023-07-19 2023-08-30 Vvb Bio Pte Ltd GP130 antigen-binding molecules
CN117085137A (zh) * 2023-10-10 2023-11-21 上海交通大学医学院附属第九人民医院 Il-11抑制剂及其在抗瘢痕治疗中的应用
CN117964734B (zh) * 2024-03-04 2025-12-26 四川大学 一种重组人白介素-11突变体及其与化学分子偶联缀合物和其制备方法与应用
GB202405551D0 (en) 2024-04-19 2024-06-05 Vvb Bio Pte Ltd Combination treatment
GB202408044D0 (en) 2024-06-06 2024-07-24 Vvb Bio Pte Ltd gp130 antigen-binding molecules
WO2026159121A1 (en) 2025-01-22 2026-07-30 VVB Bio Pte. Ltd. Bispecific molecules

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
DE69535274T2 (de) 1994-12-22 2007-06-06 Genetics Institute, LLC, Cambridge Verwendung eines menschlichen interleukin-11 rezeptors
ES2093562B1 (es) 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
US6540993B1 (en) 1995-06-27 2003-04-01 Wyeth Method of treating inflammatory bowel disease using a topical formulation of IL-11
US6126933A (en) 1995-06-27 2000-10-03 Genetics Institute Methods of treating inflammatory bowel diseases by administering IL-11
US5679339A (en) 1995-06-27 1997-10-21 Keith; James Method of using IL-11 for treating spondyloarthropies
US6649192B2 (en) 1996-07-29 2003-11-18 Universidade De Santiago De Compostela Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms
GB9702944D0 (en) 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
GB9721961D0 (en) 1997-10-16 1997-12-17 Glaxo Group Ltd Novel molecules
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CA2237915A1 (en) 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
US6953777B2 (en) 1999-03-11 2005-10-11 Genetics Indtitute LLC Use of interleukin-11 to prevent immune-mediated cytotoxicity
WO2000078336A1 (en) * 1999-06-21 2000-12-28 Genetics Institute, Inc. Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB0021668D0 (en) 2000-09-04 2000-10-18 Smithkline Beecham Plc New use
AU2002362088A1 (en) 2001-12-06 2003-06-23 Catholic University Method and composition for inducing weight loss
CA2498931A1 (en) 2002-09-16 2004-03-25 Wyeth Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods of using same
JP2007537716A (ja) 2003-12-16 2007-12-27 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼイション サイトカイン結合ドメイン
WO2005070446A1 (en) 2004-01-15 2005-08-04 Scios Inc. Method for treating cardiac remodeling following myocardial injury
US20080300147A1 (en) 2004-03-26 2008-12-04 Nasser Chegini Detection and Treatment of Fibrotic Disorders
ES2309427T3 (es) 2004-08-27 2008-12-16 Conaris Research Institute Ag Secuencias de nucleotidos optimizidas que codifican para sgp130.
JP2009518418A (ja) 2005-12-06 2009-05-07 ワイス インターロイキン１１組成物および使用法
NZ574028A (en) 2006-07-05 2010-10-29 Fibrotech Therapeutics Pty Ltd Tranilast analogues (substituted cinnamoyl anthranilate compounds) for treatment of conditions associated with firbrosis
WO2008050789A1 (en) 2006-10-27 2008-05-02 The New Industry Research Organization Use of interleukin-11 as therapeutic agent for heart disease
EP2527369A3 (en) * 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
US8182814B2 (en) 2007-10-26 2012-05-22 Csl Limited Methods of treating inflammatory airway conditions by inhibition of IL-11 activity
CA2703544C (en) 2007-10-26 2016-01-05 Manuel Baca Cytokine muteins
US8518888B2 (en) 2008-10-14 2013-08-27 Csl Limited Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R
KR101133769B1 (ko) 2011-04-18 2012-04-09 한국생명공학연구원 신규한 옥사졸리딘계 및 인돌계 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물
PT2953971T (pt) * 2013-02-07 2023-05-02 Csl Ltd Proteínas de ligação à il-11r e suas utilizações
CN105497893B (zh) 2015-12-10 2019-02-01 黑龙江省科学院高技术研究院 IL-11单克隆抗体在抑制PI3K/Akt信号通路中的应用
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
RU2016125115A (ru) 2016-06-23 2017-12-28 Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) Терапевтическое антитело, специфичное к интерлейкину-11, ингибирующее сигналирование через его рецептор, и способ его использования для лечения пациентов
GB201621431D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore The Decoy cytokine receptor
US20180186871A1 (en) 2016-12-16 2018-07-05 Singapore Health Services Pte Ltd. Il-11 antibodies
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
RU2016151730A (ru) 2016-12-28 2018-06-29 Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) Антитела для лабораторной диагностики концентрации интерлейкина-11
GB201716733D0 (en) 2017-10-12 2017-11-29 Nat Univ Singapore Treatment of SMC mediated disease
NL2020093B1 (en) 2017-12-15 2019-06-25 Stahl Int B V Process for producing aqueous polyurethane dispersions in a continuous manner; apparatus suitable for performing such a process; and products obtained by said process
GB201806918D0 (en) 2018-04-27 2018-06-13 Enleofen Bio Pte Ltd Combination treatment for eye fibrosis
GB201809699D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
GB201809700D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies

Also Published As

Publication number Publication date
AU2018229482B2 (en) 2019-08-08
US10899832B2 (en) 2021-01-26
US20180362641A1 (en) 2018-12-20
US20180362634A1 (en) 2018-12-20
CN116036284A (zh) 2023-05-02
US20180362635A1 (en) 2018-12-20
EP3428187A1 (en) 2019-01-16
HRP20181692T1 (hr) 2018-12-14
CN108495861A (zh) 2018-09-04
AU2018229486A1 (en) 2018-10-04
CN108495861B (zh) 2023-01-10
ZA201803727B (en) 2019-03-27
SMT201800601T1 (it) 2019-01-11
US10894826B2 (en) 2021-01-19
US20180362637A1 (en) 2018-12-20
US20210188962A1 (en) 2021-06-24
US10865239B2 (en) 2020-12-15
TR201815415T4 (tr) 2018-11-21
AU2018229485B2 (en) 2019-08-08
US20180371077A1 (en) 2018-12-27
AU2018229485A1 (en) 2018-10-04
US20180362639A1 (en) 2018-12-20
PL3298040T3 (pl) 2019-07-31
SG10201908380TA (en) 2019-11-28
AU2018229487A1 (en) 2018-10-04
US11939374B2 (en) 2024-03-26
AU2018229486B2 (en) 2019-08-08
WO2017103108A1 (en) 2017-06-22
EP3298040B1 (en) 2018-08-01
US20180265579A1 (en) 2018-09-20
JP6753933B2 (ja) 2020-09-09
SG11201804836RA (en) 2018-07-30
US20180362640A1 (en) 2018-12-20
US10894825B2 (en) 2021-01-19
HK1254287A1 (zh) 2019-07-19
US10894827B2 (en) 2021-01-19
AU2016369407A1 (en) 2018-08-02
JP2020189879A (ja) 2020-11-26
US20190002553A1 (en) 2019-01-03
US10927169B2 (en) 2021-02-23
US20180362636A1 (en) 2018-12-20
US10035852B2 (en) 2018-07-31
AU2018229484B9 (en) 2019-09-12
JP7102474B2 (ja) 2022-07-19
US20180362638A1 (en) 2018-12-20
EP3431500A1 (en) 2019-01-23
PT3298040T (pt) 2018-11-13
CY1120950T1 (el) 2019-12-11
US20170174759A1 (en) 2017-06-22
US10865241B2 (en) 2020-12-15
CA3007750A1 (en) 2017-06-22
KR20240152973A (ko) 2024-10-22
SI3298040T1 (sl) 2019-01-31
EP3298040A1 (en) 2018-03-28
US10870697B2 (en) 2020-12-22
AU2016369407B2 (en) 2018-09-13
RS57894B1 (sr) 2019-01-31
EP3428186A1 (en) 2019-01-16
HUE041433T2 (hu) 2019-05-28
AU2018229484B2 (en) 2019-08-08
JP2019502689A (ja) 2019-01-31
US20180371078A1 (en) 2018-12-27
US10870696B2 (en) 2020-12-22
US20180362633A1 (en) 2018-12-20
KR102720360B1 (ko) 2024-10-22
EP3431498A1 (en) 2019-01-23
KR20180097645A (ko) 2018-08-31
US10822405B2 (en) 2020-11-03
AU2018229487B2 (en) 2019-08-08
US20240360211A1 (en) 2024-10-31
EP3431499A1 (en) 2019-01-23
LT3298040T (lt) 2018-12-10
AU2018229483A1 (en) 2018-10-04
AU2018229482A1 (en) 2018-10-04
US10106603B2 (en) 2018-10-23
ES2692773T3 (es) 2018-12-05
US10889642B2 (en) 2021-01-12
AU2018229484A1 (en) 2018-10-04
US10865240B2 (en) 2020-12-15
DK3298040T3 (en) 2018-11-05
AU2018229483B2 (en) 2019-08-08
NZ744307A (en) 2019-03-29
EP3428188A1 (en) 2019-01-16

Similar Documents

Publication Publication Date Title
ZA201803727B (en) Treatment of fibrosis
IL258002A (en) Cenicriviroc combination therapy for the treatment of fibrosis
IL259110A (en) Treatment of osteoarthritis
IL247515A0 (en) Snekribirock for the treatment of leprosy
IL250960A0 (en) Combined treatment of sinecriviroc for the treatment of leprosy
IL253803A0 (en) A preparation for the treatment of hypothyroidism
IL266530A (en) Fibrosis treatment
ZA201706257B (en) Treatment of wood
SG11201609652RA (en) Treatment of polybacterials infections
GB201502137D0 (en) Treatment
GB201522243D0 (en) Treatment
IL250513A0 (en) Treatment of episode disorders
IL285882A (en) Medicinal uses for l–4–chlorokynurenine
GB2543540B (en) Decellularising tissue
IL253617A0 (en) Snekribirock for the treatment of leprosy
GB201416832D0 (en) Methods of treatment
EP3226864A4 (en) Methods of treating fibrosis
GB201508841D0 (en) Treatment
GB201503008D0 (en) Treatment
GB201514729D0 (en) Treatment of haemorrhoids
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201407806D0 (en) Treatment of fibrosis
GB201512139D0 (en) Methods of treatment
GB201510870D0 (en) Treatment of infarction
AU2014904206A0 (en) Treatment of fibrosis

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)